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ABSTRACT
Objective: The main objective of this experiment was to prepare and optimized celecoxib nanoemulgel. This formulation can be used for acute 
rheumatoid arthritis patients.
Methods: Celecoxib is a poorly water soluble drug. We prepared celecoxib nanoemulgel to improve intrinsic solubility of celecoxib and enhance 
deeper permeation throughout the skin. After several screening, the combination of acetonitrile, triacetin, campul 908P was considered for oil phase; 
acconon MC8-2EP as surfactant, and capmul MCM C-10 as a co-surfactant accordingly. As per Box-Behnken surface design model, optimization was 
done for all the 13 formulations.
Results: Based on pseudo ternary plot, it was found that 4:1 Smix ratio was optimum and possessed maximum drug solubility. Further, screening 
shown, 0.25-0.75% carbopol-940 can be a stable candidate for hydrogel preparation. Prepared nanoemulsions and hydrogels were admixed to prepare 
nanoemulgel. Based on overlay plot, EG14* formulation was consider as optimum one, and various evaluation parameters were performed along with 
other formulations. Using Franz diffusion cell, in-vitro diffusion studies was performed. Almost all the formulations produces good qualitative drug 
release profile. The EG14* shown 95.50% drug release after 12th hrs with standard Higuchi plot (R2 value 0.9989). The optimum viscosity was found 
to be 521±0.81 mPas at 100 rpm. The appearance of the formulations was milky, yellowish white with expectable pH ranged from 5.8 to 6.7. The 
optimized formulation has good spreadability coefficient, good ex-vivo diffusion enhancement factor (3.03) as compare to marketed gel. Mostly, our 
formulations have less skin irritation and higher anti-inflammatory activity (92.56% of inhibition of paw edema for EG14*).
Conclusion: From the thermodynamic studies, it was confirmed that EG14* maintained excellent stability profile in various heating-cooling cycle, 
centrifugation, and freeze-thaw cycle condition. Hence, it can be conclude that, our formulation, can be consider for pilot scale up.
Keywords: Celecoxib, Rheumatoid arthritis, Capmul MCM C-10, Box-Behnken design, Pseudo ternary plot.
INTRODUCTION
In autoimmune disease class, rheumatoid arthritis (RA) is one of 
the devastating diseases where patients suffer acute joint swellings, 
serious pain, and stiffness [1,2]. During further advancement of 
this disease, the patient may witness weight loss, moderate fever, 
anemia, and extreme tiredness. RA effects paired joints and often 
elbows, ankles, shoulders etc. In acute condition, RA causes bone 
deformations in affected areas, sometimes it leads to permanent joint 
damage. Series of complications can be seen during development of 
this disease, such as inflammation of synovium, proliferating across 
the joint surface, the inflamed joint become red and warmer as of 
maximum accumulations of blood cells on affected areas, joint capsule 
remains stretch on and after inflammation, which makes it unfit to 
hold joint in its proper position [3]. RA diagnosis is a challenging task 
because no specific test was invented to specify RA within the body; 
however, doctors often rely on X-ray, erythrocyte sedimentation 
rate, C-reactive protein, test for anemia, testing for antibodies 
such as rheumatoid factor and anticyclic citrullinated peptide, 
magnetic resonance imagining, ultrasound scan for distinctive 
characterization of RA [4]. Coming to the treatment point of view, 
there are many wide ranges of medicines are available for RA, but 
doctors prefer painkillers, non-steroidal, anti-inflammatory drugs, 
disease modifying anti-rheumatoid drugs, steroids etc., [5]. In this 
experiment, we used celecoxib, a potential cyclooxygenase-2 (COX-2) 
inhibitor which has very less adverse effect as compare to rofecoxib, 
valdecoxib etc., [6]. Celecoxib mechanism of action is very simple, it 
selectively inhibits COX-2, due to which COX-2-induced inflammation 
and prostanoids (Prostaglandin E2) synthesis cleaved [7]. Due to 
which inflammation, edema and pain end. However, celecoxib has 
very poor oral bioavailability and aqueous solubility. It is highly 
soluble in acetonitrile [8]. In this experiment, we attempted to 
prepare celecoxib nanoemulgel. Nanoemulgel which is otherwise 
known as nanoemulsion-based hydrogel, by which we have to make 
some effort to improve its permeability and diffusibility. The main 
advantages of the nanoemulgel formulation are due to the presence 
of dual nature; means hydrophilic and hydrophobic bases which can 
deeply penetrate within the skin [9-11]. Moreover, it also improves 
nanoemulsion stability by declining the surface and interfacial tension 
and also increases the viscosity of the aqueous phase for proper drug 
administration. Nanoemulgel has addition advantages such as it is 
more adhere toward skin surface and leads to higher concentration 
gradients toward skin hence assured better penetration [12-14]. The 
nanoemulgel formulation has an outstanding thixotropic profile and 
has excellent spreadability and prominent thermodynamic stability.
METHODS
Celecoxib (drug) was gifted by Prudence pharmachem-Ankleshwar, 
Gujarat. Triacetin (lipid) was procured from Himedia laboratory Pvt. 
Ltd., Mumbai. Campul 908-P (oil), Capmul MCM C-8 (co-surfactant), 
Acconon MC-8-2 EP (surfactant)-containing polyoxyethylenecapric 
glycerides were gifted by AbitecCorporation. USA. Menthol (penetration 
enhancer), dimethyl sulfoxide-extra pure (DMSO), triethanolamine was 
purchased from Siscoresearch laboratory Pvt. Ltd., Mumbai. Methyl 
paraben and propyl paraben were purchased from Lobachemical. 
Mumbai. Carbopol-940 (Gelling agent) was purchased from Corel 
Pharma Chem., Ahmedabad. Rest of the chemicals and reagents used 
during experimentation were of analytical grades. Throughout the 
experiment deionized water was used.
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Criteria for selecting excipients
Since we prepared this emulgel for topical usage, non-irritation and 
less sensitivity toward skin were our utmost priority. To maintain drug 
solubility throughout the nanoemulsion, the drug must have higher 
solubility in the oil phase. Furthermore, hydrophile-lipophile balance 
(HLB) value of surfactant has to be more than 10 for preparing a stable 
nanoemulsion. For maintaining a stable nanoemulsion, surfactant and 
co-surfactant containing higher and lower HLB value were considered 
for admixing [15,16].
Solubility study of celecoxib
The solubility of celecoxib in various oil, surfactant, and cosurfactant 
was screened out. An aliquot amount of celecoxib was added into 4 ml 
of different surfactant, cosurfactant, oils, and with deionized water 
in 10 ml vials containing stopper. Using cyclometer, the contents 
were vortexed and the temperature was maintained up to 25±1°C. 
The vials containing samples were kept in the isothermal bath for 
consistent 48 hrs to maintain equilibrium. After 48 hrs, samples were 
centrifuged at 4000 RPM for 15 minutes, and the supernatant was 
filtered using Accu-Jet® membrane filter of 0.2 µm pore size (Sigma-
Aldrich). The concentration of celecoxib in varying supernatants 
was determined by ultraviolet (UV) spectrophotometer at 255 
nm. Surfactant, cosurfactant, and oils which show better solubility 
were used for nanoemulsion preparation containing 2% celecoxib 
(Tables 1 and 2).
Construction of pseudo-ternary plot
From the solubility studies, it was confirmed that celecoxib possessed 
maximum solubility in acetonitrile + triacetin + Campul 908P oil 
mixture; hence, this mixture was considered for further extension. 
Acconon MC8-2EP as a surfactant and Capmul MCM C-10, as a 
cosurfactants showed better solubility for celecoxib and also retain 
good stability with oil phase and an aqueous phase. To investigate 
nanoemulsion region, maintaining ambient temperature up to 25±0°C, 
pseudo-ternary diagram was plotted using ProSim software. The 
surfactant and cosurfactant mixture (Smix) and oil phase were admixed 
using water titration method to form nanoemulsion. Acconon MC8-2EP 
and Capmul MCM C-10 (Smix) weight ratios (1:1, 2:1, 3:1 and 4:1) 
were taken to construct pseudo-ternary diagram. Now, Smix and oil 
were mixed in different ratios such as 1:9, 2:8, 3:7, 4:6, 5:5, 6:4, 7:3, 
8:2, 9:1, and nonoemulsion was formed using water as a titrant. Since 
celecoxib is a hydrophobic drug; hence, our target was to prepare 
water in oil nanoemulsion. From the ternary plot, all the possible 
regions of nanoemulsion formation were estimated [9,17]. Following 
tables represent the surfactants, co-surfactant (Smix): Oil:water titration 
values, which represented in pseudo-ternary plots.
Preparation of nanoemulged
Nanoemulgel was prepared by implementing simple three steps.
Step 1: Formation of nanoemulsion
From the ternary phase diagram, it was clear that 4:1 ratio of acconon 
MC8-2EP and capmul MCM C-10 (Smix) weight ratios provides maximum 
self-emulsifying property at ambient room temperature (0-25°C). 
With adequate Smix concentration, required quantities of acetonitrile, 
triacetin, campul 908P, acconon MC8-2EP, capmul MCM C-10, and 5% 
methanol was taken and admixed with 2% of celecoxib, maintaining 
the proper ratio of aqueous and oil phase. The drug was dissolved in 
aqueous phase along with surfactant and co-surfactant. The aqueous 
phase then blended with oil phase at 15000 rpm, using high-pressure 
homogenizer (Micron Lab APV, Denmark) until a milky emulsion was 
Table 2: Solubility studies of various oils, surfactants, cosurfactants
Various 
phases 
Name of the compounds used Solubility (mg/ml)±SD Remarks
Oils Triacetin 37.67±1.87 Modestly soluble 
Isopropyl myristate 10.98±0.12 Partially soluble 
Olive oil 08.24±0.58 Poorly soluble 
Arachis oil 07.23±0.19 Poorly soluble 
Captex 16.89±0.98 Sparingly soluble 
Cottonseed oil 14.09±0.11 Sparingly soluble 
Maize oil 17.38±1.23 Sparingly soluble 
Captex 09.22±2.12 Poorly soluble 
Wheatgerm oil 06.34±1.34 Poorly soluble 
Capryol 90 08.34±0.14 Poorly soluble 
Soybean oil 28.34±1.23 Modestly soluble 
IPM 02.12±0.13 Very poorly soluble 
Clove oil 17.14±0.56 Sparingly soluble 
Campul 908P 43.18±2.11 Partial highly soluble 
Triacetin+Campul 908P 54.89±0.18 Highly soluble 
Acetonitrile+Triacetin+Campul 908P 65.21±2.12 Optimum soluble composition 
Surfactants Polyethylene glycol-40 stearate 21.34±0.15 Mostly soluble 
Sorbitan mono-Oleate (Span 80) 12.35±0.14 Sparingly soluble 
Polyoxy Ethylene SorbitanMonooleate (Tween 80) 39.24±0.13 Partial highly soluble 
Cremophor RH-40 29.01±0.02 Moderately soluble 
Acconon MC8-2EP 51.24±1.23 Optimum soluble compound 
Tween 20 37.11±0.24 Partial high soluble 
Co-surfactants Ethylene glycol 05.09±1.34 Less soluble 
Propylene glycol 07.87±0.45 Less soluble 
PEG 400 9.90±0.09 Less soluble 
Capmul MCM C-10 16.09±1.20 Moderately soluble 
Captex-100 11.29±0.62 Sparingly soluble 
Capmul PG8 4.89±0.19 Poorly soluble 
Transcutol 6.89±1.96 Less soluble 
Capmul MCM L-8 5.89±2.01 Less soluble 
Table 1: Percentage transmittance with surfactant and 
co-surfactant
Surfactant % Transmittance Cosurfactant % Transmittance
Acconon 
MC8-2EP
97.38±0.05 Capmul MCM 
C-10
96.23±0.29
Tween 80 93.90±0.12 Captex-100 91.78±0.05
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formed. The celecoxib concentration was maintained constant (2%) for 
all the formulations.
Step 2: Formation of hydrogel
Hydrogels were prepared using carbopol-940, DMSO, methylparaben, 
propyl paraben, and deionized water [9].
Step 3: Formation of nanoemulgel
Prepared nanoemulsion was incorporating into hydrogel to form 
nanoemulgel formulation (Table 8).
Characterization of nanoemulsion and nanoemulgel formulations
Turbidimetric evaluation
The aliquot amount of nanoemulsion (0.8 ml) was incorporated into 
0.1 molar hydrochloric acid, and volume was maintained up to 200 ml 
using distilled water with continuous stirring using magnetic stirrer 
at ambient temperature. The turbidity was measured using digital 
nephew turbidity meter at particular equilibrium [18].
Nanoemulsion particle size analysis and zeta potential studies
Globular size and zeta potential determination are an essential part 
to identify the nanoemulsion behavior. Initially, samples were diluted 
with water at list 200 times and measured its particles/globular size 
using photon correlation spectrometer (Zetasizernano S90, Malvern 
Ltd. United Kingdom). Zeta potential can be measured by estimating 
the responses of the charged particles drift in a constant velocity. 
Furthermore, Zetasizer generates a high-frequency AC field to oscillate 
the charged particles. Using Nanotrac controlled reference technique, 
particle size distribution was measured by comparing oscillations of 
reference colloidal particles. Using MPS single zeta potential can be 
measured.
Transmission electron microscopy (TEM)
TEM was performed to characterize and evaluate morphological 
understanding of prepared nanoemulsion. TEM was performed using a 
JEM-ARM 200F instrument (JEOL solutions for innovation corporation-
USA) which operates at 200 kv.
Mathematical modeling
Using design expert® 7.0 software, it was possible to find which model 
is best suits for correlation between independent and dependent 
variables. The software itself selects a suitable model on the bases of 
individual parameters generated from regression analysis, such as 
adjusted R2 value, Predicted R2 value and predicted residual sum of 
square (PRESS) and p value. At 5% level of significance, analysis of 
variance was implemented. Here, more than one model was found to 
be significant; hence, best-fit model was screened out by analyzing 
adjusted R2 value, which has to be higher in denomination but <1, 
and PRESS value which has to be lower in value. The general quadric 
equation for three independent variables is as follows:
Y  +X +X +X +X X +X
X +X X +X +X
0 1 1 2 2 2 3 1 2 4 1





= β β β β β
β β β β  (1)
β0 represent the arithmetic outcomes average of all the outcomes of 
experimentation-13 batches. β1 to β9 represents the coefficient of 
observed experimental values of Y1 to Y2. On the other hand, X1, X2, and X3 
are the coded level of factors. X1 to Xn (n = any number) represent quadric 
terms and interaction, respectively. The coefficient of one factor signifies 
the effect of particular factor and interaction of two-factor represents 
the quadric nature and effect between those two factors, respectively. 
In front of factors if the negative sign arose, the nit indicates that it has 
an antagonistic effect on design; on the other hand, the positive sign 
represents the synergistic effect on design model (Table 7).
Appearance and pH determination
The prepared nanoemulged were evaluated based on physical 
examination first. The product homogeneity, consistency, color, and 
pH were determined. The freshly prepared products were stable and 
maintained light milky yellowish appearances. The pH was determined 
using digital pH meter (Mettler instrument, Germany) by taking 1% of 
prepared nanoemulgel in double distilled water [19].
Viscosity
The viscosity of the different nanoemulgel was determined using 
Brookfield Digital Viscometer (LVDV III Ultra, Brookfield Engineering 
Laboratories, and the USA) at 25°C. The t-92 number spindle was taken, 
and viscosity was recorded at different rotational speeds of 10, 20, 50, 
and 100 rpm [20].
Drug content
1 ml of nanoemulgel was diluted to 20 ml of methanol and sonicated. 
The volume was maintained up to 100 ml using phosphate buffer 
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(pH7.4). The UV-VIS spectrophotometer (SHIMADZU-1880) was used 
to measure celecoxib content after several dilutions of nanoemulgel at 
255 nm.
Spread ability studies
As per Jain et al., spreadability of prepared nanoemulgel was measured 
using two different glass slides (7.5×2.5 cm). The first slide was bound 
with wooden frame. On top of the first glass slide, 1 g of nanoemulgel 
was allocated, and second glass slide was placed over first glass side. 
Furthermore, 100 g weight was imposed over second glass top. Due 
to overweight, entrapped air between the sandwiched nanoemulgel 
was removed. Using thread and progressive weights, the second glass 
slide was pulled up to pre-set distance of 7.0 cm. The time (second) and 
weight (g) required to mobilized second slide up to 7 cm was measured. 




where M is the weight (g) tied to the second slide. L is the length of the 
glass slide. T is the time taken to separate two glass sides [21].
In-vitro diffusion studies
Using Franz diffusion cell, dialysis studies was been carried out. 
Prepared nanoemulged (1 g) was eventually applied onto the surface of 
the dialysis membrane. The dialysis membrane was clasp between donor 
and receptor compartments. The receptor compartment was filled with 
Ph 7.4 phosphate buffer solution. The receptor compartment solution 
was stirred constantly using 2.5 cm long magnetic beads maintaining 
the temperature at 25°C. The aliquots amount of samples were (1 ml) 
withdrawn conservatively from 1 to 12 hrs interval, and simultaneously, 
1 ml of fresh 7.4 pH phosphate-buffered solution was poured into donor 
compartment. The various samples of each time interval were analyzed 
using UV-VIS spectrophotometer (SHIMADZU-1880) at 255 nm at 
appropriate dilutions.
Ex-vivo diffusion studies
Using averted rat skin of a pre-sacrificed animal, ex-vivo diffusion 
studies were carried out. Same in-vitro diffusion procedure was been 
followed for this experiment. Ex-vivo parameters were calculated by 
calculating cumulative correlation of drug diffused per unit time. The 
average cumulative amount of the drug permitted through the unit 
surface of the skin was plotted against time in an hour. From the plot, 
the slope of the linear portion was calculated [22]. It was considered as 





Hear, Cv and Jss stands for the total amount of the drug and 
permeability coefficient of the drug, respectively [23]. Due to the 
formation of nanoemulgel formulation, the enhancement of the drug 
permeation would be higher than the marketed product [Note: Due to 
unavailability of marketed product, we prepared celecoxib gel as per 
Karade et al. article] [24]. The enhancement factor was calculated as 
per the following equation:
The enhancement factor [EF] = 
Kp of nanoemulgel formulation
Kp of marketed gel  
Acute skin irritation studies
Skin irritation studies were carried out at Deshpande laboratory, 
Bhopal-India, according to the approval of Animal Ethical Committee 
[1410/c/11/CPCSEA]. As per modified Draize et al. (1944) method, the 
selected three rabbits for experiments were acclimatized according to 
the laboratory condition prior 1 week of the experiments. Humidity 
and temperature of the experimental room were maintained up to 
45% RH and 25°C, respectively. The dorsal side of the skin of the 
selected three rabbits was trimmed (5 cm), and the first rabbit was 
considered for negative control, where no treatment was given. The 
second rabbit was considered for the test, where 4 g of nanoemulgel 
was introduced into its trimmed dorsal skin, and the third animal 
was treated with formalin (0.8%v/v), which is consider as a standard 
irritant. This process was continued for 6 days. On the 7th day, the 
dorsal skin of all the three rabbits was cleaned with distilled water. 
The treated skin was examined by visual observation for erythema 
and edema [25].
Anti-inflammatory activity studies
As per Animal Ethical Committee [1410/c/11/CPCSEA] approval, anti-
inflammatory activity was performed for prepared nanoemulgel. Totally, 
three groups (3×3) of Wistar rats containing average 200 g weight of 
either sex were selected. The animals were caged in polypropylene 
boxes, and adequate diets were given before starting the experiment. 
The animals were maintained as per standard laboratory conditions, 
at 25±1°C and 50-55% RH. Controlled group (first group) of animals 
was maintained untreated. Remaining two groups of rats were induced 
with 1% w/v carrageenan solution by subcutaneous route to produce 
paw edema. After injection, 1 day was waited to observe edema effect 
on animals paw. Next day, the second group of animals was treated 
with optimized 20-25 mg of nanoemulgel formulation followed by the 
third group of animals with 30 mg marketed product (Karade et al.). 
The paw volume was measured using plethysmometer for consecutive 
1-12 hrs. The percentage inhibition of edema was determined against 
the controlled group [26,27].
Thermodynamic stability studies
Thermodynamic stability studies are an integral part to screen out 
metastable formulations. Since we prepared nanoemulgel, which has 
to be free from phase separation, cracking and creeming, and all other 
associated stability issues. To understand that in details we investigate 
our all products in three different conductions. At first, formulation was 
centrifuged at 4000 rpm for 30 minutes. Those formulations which did 
not shown any phase separation considered for extreme heating and 
cooling studies, where temperature maintained up to −40-450°C. Best 
formulation which passed the previous experiment, was considered 
for freeze-thaw cycle test, where formulations were charged for 48 hrs 
at −210°C to +250°C. The formulation which intact good stability was 
considered as best formulation.
RESULTS AND DISCUSSION
Screening of excipients and solubility studies
Based on higher solubility within the drug molecule and 
emulsification ability, the combination of acetonitrile + triacetin + 
Campul 908P was selected for oil phase [solubility: 65.21±2.12]. 
Acconon MC8-2EP was selected as surfactants because of its 
optimum solubility [51.24±1.23] and maximum emulsification 
ability, at the same time, our surfactant has HLB value more than 10. 
Due to the usage of single surfactant transient, negative interfacial 
tension and fluid interfacial film are rarely achieve. After much 
more screening, Capmul MCM C-10 was selected as cosurfactant 
because of its higher solubility potential with the drug [51.24±1.23]. 
Our surfactant was less ionic in nature; hence, less toxicity can 
be escalated. Furthermore, powerful biological expectancy and 
permeation enhancement could be possible.
From the obtained results, it can be concluded that the combination of 
acetonitrile + triacetin + Campul 908P, exhibits maximum emulsification 
ability with Acconon MC8-2EP [97.38%]. The gradual addition of 
cosurfactant as Capmul MCM C-10 improves dispensability and shown 
maximum transmission of 96.23% followed by Captex-100 of 91.78% 
transmission (Tables 1 and 2).
Construction and outcome of pseudo-ternary diagram
Formation of various pseudo ternary phase diagram by utilizing 
the ratio of oil, Smix and water represent the nanoemulsion region 
and optimized concentration of mixture [17]. The various yellow 
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color shade areas within the pseudoternary phase diagrams 
represent stable emulsion phase, where clear and transparent 
w/o nanoemulsion was formed (Figs. 1-4). Rest of the white area 
represents conventional and turbid non-optimized emulsion. The 
various output of Acconon MC8-2EP and Capmul MCM C-10 (Smix) 
weight ratios (1:1, 2:1, 3:1, 4:1) were tabulated and represented 
bellow in Tables 3-6, respectively.
It was observed that increased concentration of surfactant (4:1) 
produces maximum nanoemulsion region. Further increasing the 
concentration of surfactants could produce toxicity. Hence, apseudo 
ternary diagram of Smix 4:1 was selected for drug loading nanoemulsion.
TEM
The TEM study was performed to correlate morphology, the structure 
of the particles along with obtained particle size. The prepared 
nanoemulsion was diluted with double distilled water in 1/100 times. 
One drop of the diluted emulsion was poured in holey film grid of TEM 
and dried. After drying, point-to-point estimation of particles was done 
using TEM. The droplet size of nanoemulsions was found to be aligned 
with previously obtained particle size results (Fig. 5).
Turbidimetric evaluation
Turbidity of the prepared nanoemulsions were determined using 
Manti Lab 0-100 NTU Digital Turbidity Meter MT-134. The various 
formulations such as EG2, EG7, EG11, and EG13 possessed maximum 
turbidity because of higher percentage of oil phase. The globular size 
of the particles was also higher in those formulations. However, EG1, 
EG7, EG10, and EG12 formulations were constrained with less turbidity, 
because of higher percentage of surfactant, which considerably governs 
particle size and its distribution.
Particle size analysis
Using laser scattering microscopy particle size has been determined. 
The droplet size increase with increase in concentration of acetonitrile 
+ triacetin + Campul 908P [oil phase] concentration. On the other hand, 
decreased concentration of oil in EG1, EG3, EG5, and EG9 produces 
lesser droplet size. Maximum droplet size was around in nanoscale. 
The particle size was alter with HLB value of the surfactant and 
co-surfactant concentration. EG13 formulation possessed maximum 
concentration of oil and minimum concentration of surfactant, 
hence, it produces maximum droplet size within all the formulations 
(456±1.67 nm). However, the droplet size of the particles ranged from 
234 to 456 nm. Zeta potential was around −6.23±0.23 to −1.39±1.90, 
which is indicating that the nanoemulsion particles are non-aggregative 
and cationic in nature.
Effect of formulation variables on viscosity of the prepared 
nanoemulgel
As per Box-Behnken surface design output, quadric model output 
was projected. After the screening of analytical data, it was found that 
Table 7: Observation and variable responses of Box-Behnken factorial design for various nanoemulgel formulations (mean±SD, n=3)
Formulations Independent variable (coded) Independent 
variables (actual)
Dependent variables
X1 X2 X3 X1 X2 X3 Y1 (viscosity) Y2 (% drug diffusion)
EG1 −1.000 1.000 0.000 20.00 60.00 0.50 785 87.36
EG2 1.000 0.000 −1.000 60.00 45.00 0.25 689 88.32
EG3 −1.000 −1.000 0.000 20.00 30.00 0.50 876 81.108
EG4 0.000 −1.000 −1.000 40.00 30.00 0.25 593 83.01
EG5 1.000 0.000 1.000 20.00 45.00 0.75 1176 85.34
EG6 0.000 0.000 0.000 40.00 45.00 0.50 987 86.82
EG7 1.000 1.000 0.000 60.00 60.00 0.50 1098 92.703
EG8 0.000 −1.000 1.000 40.00 30.00 0.75 1351 85
EG9 1.000 0.000 −1.000 20.00 45.00 0.25 588 83.12
EG10 0.000 1.000 −1.000 40.00 60.00 0.25 557 88.86
EG11 1.000 0.000 1.000 60.00 45.00 0.75 1589 90.501
EG12 0.000 1.000 1.000 40.00 60.00 0.75 1284 91.1
EG13 1.000 −1.000 0.000 60.00 30.00 0.50 1077 86.28
Where, Independent variables, X1: Acetonitrile+triacetin+Campul 908P (oil), X2: Acconon MC8-2EP and Capmul MCM C-10 (Smix), X3: Carbopol 940 (thickening agent).
Dependent variables, Y1: Viscosity at 100 rpm, Y2: % of drug diffusion at 12th hrs 
Fig. 1: Pseudo-ternary diagram of 1:1 Smix ratio
Fig. 2: Pseudo-ternary diagram of 2:1 Smix ratio
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quadric model has higher adjusted R2 value (0.9996), less PRESS value, 
and expectable p-value (0.0029) [Table 12 and 14] and less PRESS value 
[Table 13]. Hence, quadric model was considered as optimum model. 
The polynomial equation as per the coded factor was incepted bellow.
Viscosity at 1  rpm Y1 987 128 5 X 21 63X
371 63X
1 2

















From the quadric equation 2, it can be postulated that Viscosity has 
higher average arithmetic outcome average +987(βo) (Table 11) 
carbopol-940 (X3) has massive influence on increasing viscosity because 
coefficient of X3 (371.63) was much higher than X1 (128.50). On the 
other hand, Smix concentration (X2) has antagonistic effect on viscosity 
because X2 coefficient was in minus (−21.63). The oil and carbopol-940 
mixture (X1X3) have maximum susceptibility to produce maximum 
viscosity because it has maximum coefficient value (78.00) as compare 
to oil and surfactant mixture (X1X2), which is 28.00. The mixture of 
Smix and carbopol-940 produces antagonistic results. Further analysis 
shows double concentration of oil can increase viscosity (as  coefficient 
was 18.13) but double concentration of carbopol-940 may have less 
influence on viscosity, due to negative relation of carbopol-940 within 
the system (Fig. 6).
Non-linearity of the 3D model was inclined toward oil phase, indicating 
viscosity was depends on increasing concentration of oil phase. At 
an optimum concentration of carbopol-940 (0.50), the viscosity was 
showing around 780 mPas. Design points also indicating viscosity was 
depended on carbopol-940 concentration. The linear plot with expected 
and predicted value signifies the perfect correlation of the model. From 
the box-cox plot of power transfer graph, it was observed that the blue 
color line was found to be within the red color line, indicating the model 
is in the optimized zone and no significant changes require for response 
transformation. Regression analysis of viscosity (Y1) with oil mixture 
(X1), Smix (X2) and carbopl-940 (X3) indicating good correlation 
between the variables (Table 9).
Effect of formulation variables on % drug diffusion on 12th hrs
As per Box-Behnken surface design output, linear model output 
was projected. After the screening of analytical data, it was found 
that linear model has higher adjusted R2 value (0.9984), expectable 
p-value (<0.0001) [Table12 and 14] and less PRESS value (0.36) 
[Table 13]. Hence, a linear model was considered as an optimum 
model. The polynomial equation as per the coded factor was incepted 
bellow.
% of Drug diffusion at 12th hr (Y2) = +86.89+2.61X1+3.08X2+1.08X3 (3)
From the equation 3, it can be confirmed that % drug diffusion has 
lower average arithmetic outcomes as compare to viscosity  and all 
the independent (Table 11) variables (X1, X2, and X3) have agonistic 
effect with drug diffusion at the 12th hr because of positive sign of 
all the coefficient associated with X1, X2, and X3. Furthermore, it can 
be concluded that Smix (X2) has higher influence and concentration of 
Carbopl-940 (X3) has less influence on drug diffusion at the 12th hr 
because of higher coefficient of X2 (3.08) and lower coefficient of X3 
(1.08).
From the 3D plot, it can be assumed that the linear relationship was 
established between Smix and % oil. The steeper ascent of the graph 
progressively ascending from the midpoint of Smix and % oil, indicating 
agonizing effect of X1, X2 on % drug release at the 12th hr. As per design, 
the drug optimum diffusion would be around 88%. The linear plot with 
expected and predicted value signifies the perfect correlation of the 
model. From the box-cox plot of power transfer graph, it was observed 
that the blue color line was found to be within the red color line, 
indicating the model is in the optimized zone and no significant changes 
require for response transformation (Fig. 7). Regression analysis of % 
drug diffusion at 12th hrs (Y2) with oil mixture (X1), Smix (X2) and 
carbopl-940 (X3) indicating good correlations between the variables 
(Table 10). 
Optimization and screening from overlay plot
The yellow color surface indicating optimized zone in which EG14* has 
a best-optimized viscosity at 790.34 mPas, %drug diffusion at 87.35%. 
These statistical responses are predicted by Design Expert 7.0 software. 
Considering these facts, our experimental or actual responses for 
viscosity was found to be 791.08 mPas and for percentage drug diffusion 
Fig. 3: Pseudo-ternary diagram of 3:1 Smix ratio
Fig. 4: Pseudo-ternary diagram of 4:1 Smix ratio
Fig. 5: Transmission electron microscopy analysis of prepared 
nanoemulsion
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it was 88.12%. The % error for viscosity and percentage drug diffusion 
was estimated to be as 0.093% and 0.873% respectively, which was far 
lesser than 9% of the actual limit. Hence, it can be concluded that EG14* 
formulation turn out to be best-optimized formulation for nanoemulgel 
preparations. (Fig. 8 and Table 15).
The viscosity of nanoemulgel
Viscosity was determined using the previously mentioned procedure. 
Initially prepared hydrogel viscosity was depended on sharing the 
stress. However, it was observed that increase rpm could lead to 






Fig. 7: (a-d) Counterplot, 3D modeling, predicted versus actual value and box-cox plot of % drug diffusion at the 12th hr as per 




Fig. 8: Overlay plot and screening out optimum formula from the 
graph
Fig. 9: % Cumulative drug release profile of all the nanoemulgel 
formulations
360
Asian J Pharm Clin Res, Vol 10, Issue 8, 2017, 353-365
 Bhattacharya and Prajapati 
Fig. 10: EG14* of checkpoint batch showing excellent kinetic profile and maximum R2 value in Higuchi kinetic model
Fig. 11: Spread ability profile of all the formulation
decrease in viscosity [27]. It was because unarranged particles started 
arranging within the direction of flow in the longitudinal axis. However, 
increase concentrations of carbapol-940 enhance viscosity. Further, 
addition of Smix and oil mixture alters the viscosity and share thinning 
profile of the prepared nanoemulgel. The various viscosity profile at 
different rpm was mention in Table 18.
Content uniformity
Almost all the formulation retained good drug content. However, EG11 
possessed higher drug content as 98.18%, and E10 formulation scored 
lest in drug content as 92.01%.
Physical appearance and pH determination
The various formulated nanoemulgels was found to have milky 
yellowish white in appearance. Almost all the formulations have a good 
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consistency. The pH of these formulations was ranged between 5.8 
and 6.7. Which are considerably acceptable and less irritable for use in 
human skin, as human skin pH is 5.5.
Spread ability studies
Spread ability studies were performed as per described procedure. The 
spread ability of the prepared nanoemulgel was depended on polymer 
Table 8: Formulation table
Ingredients (% w/w) EG1 EG2 EG3 EG4 EG5 EG6 EG7 EG8 EG9 EG10 EG11 EG12 EG13
Celecoxibe 2 2 2 2 2 2 2 2 2 2 2 2 2
Acetonitrile+triacetin+Campul 
908P [X1]
20 60 20 40 20 40 60 40 20 40 60 40 60
Acconon MC8-2EP+Capmul 
MCM C-10 [X2]
60 45 30 30 45 45 60 30 45 60 45 60 30
Menthol 5 5 5 5 5 5 5 5 5 5 5 5 5
DMSO 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5
Methyl paraben 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02
Propyl paraben 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Carbopol-940 [X3] 0.50 0.25 0.50 0.25 0.75 0.50 0.50 0.75 0.25 0.25 0.75 0.75 0.50
Triethanolamine 
(To adjust the Ph up to 6-6.5)
Qs Qs Qs Qs Qs Qs Qs Qs Qs Qs Qs Qs Qs


























Table 9: Regression analysis of viscosity (Y1) with oil mixture (X1), Smix (X2) and carbopl-940 (X3)
Source df SS MS F Significance F
Regression 3 1240680.25 413560.0833 99.74203066 3.17473E-07
Residual 9 37316.67308 4146.297009 - -
Total 12 1277996.923 - - -
Table 10: Regression analysis of % drug diffusion at 12th hrs (Y2) 
with oil mixture (X1), Smix (X2) and carbopl-940 (X3)
Source df SS MS F Significance F
Regression 3 139.5865 46.52884 2540.762 1.72E-13
Residual 9 0.164817 0.018313 - -
Total 12 139.7513 - - -
Table 11: Polynomial coefficient for Y1 and Y2











Table 12: Fit summary of highest order polynomial measured 
responses of the independent variables
Source Y1 Y2
f value p value f value p value 
Linear versus mean 99.74 <0.0001 2540.76 <0.0001
2FI versus linear 5.77 0.0335 0.33 0.8047
Quadratic versus 2FI 68.98 0.0029 0.96 0.5141
consistency and viscosity of oil phase and polymer concentration. More 
viscous formulation would have less spread ability. It is expressed 
to understand the maximum surface area of the skin, in which the 
formulation spreads over. On the contrary, spread ability has a direct 
impact on drug distribution and penetration throughout the skin. From 
this column graph, it was estimated that EG10 formulation secured 
maximum spread ability coefficient (Fig. 11).
In-vitro diffusion studies or cumulative drug release
In-vitro diffusion studies using Franz diffusion cell and dialysis 
membrane helps to identify overall release patterns of the formulations. 
Almost all the formulation maintained good release profile, but EG1, 
EG7, EG10, and EG12 possessed optimum releases, as Smix concentration 
was higher in those formulations. Moreover, most formulations turn 
out liquid after finishing of this experiment, indicating higher diffusion 
throughout dialysis membrane. After Box-Behnken factorial design of 
the experiment, EG14* formulation was developed out, within all those 
13 formulations. The drug release patterns or diffusion from EG14* 
was very steady, after 12th hr it released 95.50% of drug within that 
formulation (Fig. 9 and Table 16). EG14* had also shown excellent 
kinetic profile. From the R2 value (0.9989) it was predicting that 
mechanism of drug diffusion is Higuchi (Fig. 10 and Table 17).
Ex-vivo diffusion studies
For this study, we took EG14* as our optimized formulation and prepared 
celecoxib gel as per Karade et al. article as CG. It was observed that 
after the 12th hr of diffusion EG14* possessed 95.50% cumulative drug 
release, where else CG formulations delivered 56.90% cumulative drug 
release only. The optimized formulation exhibits maximum permeation 
coefficient (412.51 µg/cm2/h) as compare to CG formulation (135.67 
µg/cm2/h) when drug concentration was consider as 20 mg. The 
permeation enhancement factor was compared between EG14* and CG 
formulation. The enhancement factor was found to be 3.03 (Fig 12).
Acquit skin irritation test
Prepared nanoemulgel skin irritation study was performed to estimate 
the safety index of the formulation. It was observed that prepared 
nanoemulgel was very tolerated by rabbit’s skin and shown less 
standard deviation on skin irritating score (0.8164) as compare to a 
standard irritant (1.34). No sign of erythema was observed in the test 
as compare to a standard irritant. Hence, our product maintained less 
skin irritation.
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Table 13: Model summary statistics of response to select the best model to fit data
Sources Linear 2FI Quadric
Responses Adjusted R2 Predicted R2 PRESS Adjusted R2 Predicted R2 PRESS Adjusted R2 Predicted R2 PRESS
Y1 0.9611 0.9357 82170.45 0.9850 0.9587 52802.27 0.9996 - ±
Y2 0.9984 0.9974 0.36 0.9980 0.9945 0.77 0.9979 - +
N.B: + Case(s), in above of 1.0000: PRESS statistic not defined
Table 14: ANOVA table for measured responses
Model terms Viscosity (Y1)-quadric model % Drug diffusion (Y2)-linear model
f value p value f value p value
Model 3103.48 <0.0001 2540.76 <0.0001
X1 2887.39 <0.0001 2974.72 <0.0001
X2 81.77 0.0029 4139.08 <0.0001
X3 24149.53 <0.0001 508.48 <0.0001
X1X2 68.55 0.0037 - -
X1X3 531.93 0.0002 - -
X2X3 5.25 0.1058 - -
X12 16.41 0.0271 - -
X22 106.29 0.0019 - -
X33 1.44 0.3158 - -
ANOVA: Analysis of variance
Table 15: Composition and results from checkpoint batches containing predicted and experimental values
Formulation Independent 
variable’s





EG13 % Oil [X1] 60 Viscosity % drug diffusion 1025 1077 4.82
% Smix [X2] 30 84.67 86.28 1.86
% Carbopol-940 [X3] 0.50
EG14* % Oil [X1] 20.80 Viscosity % drug diffusion 790.34 791.08 0.093
% Smix [X2] 59.50 87.35 88.12 0.873
% Carbopol-940 [X3] 0.50
EG6 % Oil [X1] 40 Viscosity % drug diffusion 984 987 0.303
% Smix [X2] 45 85.67 86.82 1.32
% Carbopol-940 [X3] 0.50
EG14* batch produces more accurate results as compare to overlay plot
 Table 16: % In-vitro cumulative drug release of nanoemulgel EG1 to EG14* 
Time in hour EG1 EG2 EG3 EG4 EG5 EG6 EG7 EG8 EG9 EG10 EG11 EG12 EG13 EG14*
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
1 32.67 31.47 33.67 35.12 33.87 34.12 36.12 32.12 34.11 35.18 32.18 31.87 33.98 27.68
2 39.23 38.19 39.18 41.65 43.17 45.18 46.01 43.11 45.19 42.98 43.19 44.11 44.19 38.39
3 43.23 43.76 43.87 45.71 45.87 49.32 50.51 46.53 47.38 45.62 47.72 49.56 48.52 47.12
4 46.11 48.25 45.17 50.11 49.58 54.18 56.28 50.61 52.67 49.82 53.78 54.17 51.34 53.78
5 52.47 53.67 50.91 54.17 55.43 59.28 61.57 53.18 56.18 54.71 58.13 59.01 55.21 60.20
6 57.28 60.21 55.71 58.17 60.34 62.48 66.29 57.71 59.52 59.72 64.11 64.88 57.21 64.11
7 63.78 65.19 59.14 63.17 64.44 67.21 70.27 61.41 63.09 63.62 69.42 67.66 63.18 70.62
8 69.72 70.67 63.81 66.28 69.41 70.17 75.61 65.12 66.32 67.51 74.61 73.71 67.03 74.61
9 73.15 75.16 67.17 70.12 73.09 74.48 80.17 69.81 69.98 73.57 78.24 79.32 71.62 77.24
10 76.41 79.45 72.71 74.62 78.72 78.61 84.85 74.28 73.19 78.34 81.98 84.16 76.83 83.23
11 82.78 84.19 76.51 77.15 81.78 83.19 87.11 78.18 78.42 84.58 86.41 87.23 80.18 86.41
12 87.36 88.32 81.108 83.01 85.34 86.82 92.703 85 83.12 88.86 90.501 91.1 86.28 95.50
In-vivo anti-inflammatory effect
As par Winter et al. paw edema test, optimized formula EG14* and 
marketed gel of celecoxib (as per Karade et al. article-CG) was evaluated 
for carrageenan-induced edema and anti-inflammatory activity. It was 
found that after EG14* formulation induction, the paw edema volume 
was significantly reduced and it was estimated using plethysmometer. 
After 12 hrs of nanoemulgel administration in induced edema area, it 
was found that higher of 92.56% edema volume was gone compare to 
marketed 79.67%. Its shows better penetration of drug throughout the 
skin and due to less viscosity, the canonization of drug and effective 
spread ability (Fig. 13).
Thermodynamic stability studies
As per previously described method, thermodynamic stability testing was 
done and it was cross-verified that no characteristic creaming, cracking, 
and phase separation was observed. Various stress testing experiment 
such as heating-cooling, centrifugation, the freeze-thaw cycle was 
performed. Almost all the formulation passes the stability stress testing. 
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Table 17: Kinetic studies of drug release profile of formulation batches
Formulation code R2 value
Zero order First order Higuchi Hixon-Crowell Korsmeyer-peppas Best fit model
EG1 0.7938 0.9323 0.9627 0.9122 0.7283 Higuchi
EG2 0.8397 0.9586 0.9812 0.9406 0.7759 Higuchi
EG3 0.7584 0.9113 0.9460 0.8907 0.690 Higuchi
EG4 0.7626 0.9163 0.9524 0.8943 0.7052 Higuchi
EG5 0.7858 0.9234 0.9614 0.9018 0.7302 Higuchi
EG6 0.7936 0.9228 0.9695 0.8997 0.7553 Higuchi
EG7 0.8077 0.9458 0.9739 0.9229 0.7585 Higuchi
EG8 0.7662 0.8899 0.9569 0.8679 0.7323 Higuchi
EG9 0.7608 0.8946 0.9538 0.8720 0.7225 Higuchi
EG10 0.7678 0.9192 0.9526 0.8974 0.7071 Higuchi
EG11 0.8346 0.9502 0.9839 0.9291 0.7911 Higuchi
EG12 0.8329 0.9455 0.9838 0.9235 0.7969 Higuchi
EG13 0.7386 0.8711 0.9444 0.8495 0.7071 Higuchi
EG14* 0.8958 0.9774 0.9989 0.9605 0.8638 Higuchi
Table 18: Viscosity of nanoemulgel formulation at different rpm
Formulation code Determination of viscosity in mPas at different RPM, maintaining temperature at 25°C
10 rpm 20 rpm 50 rpm 100 rpm
EG1 3567±0.78 3086±0.18 1678±0.22 785±0.67
EG2 3171±1.98 2607±0.32 1349±0.11 689±0.37
EG3 3678±0.89 3291±0.28 1790±0.39 876±0.11
EG4 2987±1.78 2589±0.28 1290±0.71 593±0.38
EG5 5209±0.86 4898±0.55 2778±0.55 1176±0.29
EG6 4378±1.75 3813±0.28 1983±0.39 987±0.19
EG7 4920±0.89 4281±0.77 2590±0.11 1098±0.37
EG8 5518±1.28 5089±0.29 2890±0.52 1351±0.62
EG9 2890±0.88 2471±0.37 1289±0.72 588±0.45
EG10 2789±0.11 2390±0.73 1027±0.52 557±0.31
EG11 5678±0.48 5078±0.38 2467±0.19 1589±0.54
EG12 5467±0.28 5036±0.73 2411±0.73 1284±0.58
EG13 5024±0.61 4690±0.49 2247±0.39 1077±0.11
EG14* 2741±0.11 2490±0.13 1011±0.30 521±0.81
Table 19: Comparison of optimized parameters of EG14* and CG formulation in ex-vivo studies
Formulation Jss in µg/cm2/hr Kp in cm/hr×10−3 Cumulative percentage 
drug diffused at 12th hr
EG14* 412.51 20.62 95.50%
CG 135.67 6.78 56.90%
Table 20: Acquit skin irritation study outcomes on rabbits
Groups Treatment Score after days Mean score Standard deviation
1 2 3 4 5 6 7
Negative control No treatment 0 0 0 0 0 0 0 0 0
Test 4 g prepared nanoemulgel 3 3 2 2 2 1 1 2 0.8164
Standard irritant 0.8%v/v formalin 8 7 7 6 6 5 4 6.14 1.34
Table 21: Anti-inflammatory effects of NEG 14* and CG in carrageenan induced rat paw edema
Group Formulation N Time (hour) Mean % oedema±SD % Inhibition
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(Table 21: Continued)
Group Formulation N Time (hour) Mean % oedema±SD % Inhibition






































EG1 × √ √
EG2 √ √ √
EG3 √ √ √
EG4 × √ √
EG5 × × √
EG6 √ √ √
EG7 × √ √
EG8 √ √ √
EG9 √ √ √
EG10 √ √ √
EG11 √ √ √
EG12 √ √ √
EG13 √ √ √
EG14* √ √ √
It can be a conclusive evidence that efficacy of surfactant, cosurfactant, 
and oil was unaffected after exposing it to hostile conditions.
CONCLUSION
In topical drug delivery system, nanoemulgel formulations could be 
considered as a very recent approach, in which both the hydrophobic and 
hydrophilic drug can be formulated and quantified desire effects. Our 
study highly emphasized on proper optimization, design, development, 
delivery approach of a poorly water soluble drug called celecoxib. 
Based on higher solubility and HLB value, we categorically screened out 
proper oil, surfactant, and co-surfactant to prepare nanoemulsion first. 
Later, we have selected proper polymer for nanoemulgel formulation. 
From the pseudo-ternary phase diagram, it has been reviled that 4:1 
ratio of Smix could produce good solubility, stability, and penetrability. 
Moreover, turbidimetric studies, particle size determination studies, 
and TEM concluded that prepared nanoemulsion retained within the 
nano range. Furthermore, Box-Behnken factorial design was used to 
optimizenanoemulgel formulations. Almost all the 13 formulations 
Fig. 12: Percentage cumulative amount of drug diffusion profile of 
EG14* and CG at 12th hr
Fig. 13: Comparison of effect of anti-inflammatory activity of 
EG14* and CG gel
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possessed good appearance and pH, good viscosity, drug diffusibility, 
spread ability, and the cumulative percentage of drug release. The overlay 
plot we had given best out of best formulation named as EG14* and found 
it has good percentage cumulative drug release profile, diffusion profile, 
almost 92.56% of inflammatory inhibition, and possessed handsome 
stability profile. Hence, it can be concluded that prepared celecoxib 
nanoemulgel was a good candidate for topical drug delivery system.
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